Data / Drug companies / Lisdexamfetamine dimesylate
Lisdexamfetamine dimesylate: 16 companies and 147 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Lisdexamfetamine dimesylate is listed in the FDA National Drug Code Directory by 16 companies, with 147 products in commercial distribution. 134 of the products (91.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; tablet, chewable, and the newest product started marketing on December 24, 2025.
The request: Get every company that lists lisdexamfetamine dimesylate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 16
- Products
- 147
- Generic (ANDA) products
- 134 (91.2%)
- Application numbers
- 20
- Controlled substance schedule
- Schedule II
- Routes
- Oral
- Brand names
- Vyvanse
- openFDA record search
- api.fda.gov
Companies that list lisdexamfetamine dimesylate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Camber Pharmaceuticals, Inc. | 13 | capsule; tablet, chewable | Generic drugs (ANDA) | September 9, 2024 |
| Granules Pharmaceuticals Inc. | 13 | capsule; tablet, chewable | Generic drugs (ANDA) | January 29, 2025 |
| SpecGx LLC | 13 | capsule; tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Sun Pharmaceutical Industries, Inc. | 13 | capsule; tablet, chewable | Generic drugs (ANDA) | August 25, 2023 |
| Takeda Pharmaceuticals America, Inc. | 13 | capsule; tablet, chewable | New drug applications (NDA) | January 28, 2017 |
| Teva Pharmaceuticals, Inc. | 13 | capsule; tablet, chewable | Generic drugs (ANDA) | December 17, 2024 |
| Bryant Ranch Prepack | 8 | capsule | Generic drugs (ANDA) | January 30, 2024 |
| Alvogen Inc. | 7 | capsule | Generic drugs (ANDA) | August 25, 2023 |
| Apotex Corp. | 7 | capsule | Generic drugs (ANDA) | November 9, 2023 |
| Elite Laboratories, Inc. | 7 | capsule | Generic drugs (ANDA) | November 15, 2024 |
| Hikma Pharmaceuticals USA Inc. | 7 | capsule | Generic drugs (ANDA) | January 17, 2024 |
| Lannett Company, Inc. | 7 | capsule | Generic drugs (ANDA) | August 25, 2023 |
| Rhodes Pharmaceuticals LLC | 7 | capsule | Generic drugs (ANDA) | January 30, 2024 |
| Sandoz Inc | 7 | capsule | Generic drugs (ANDA) | September 16, 2025 |
| American Health Packaging | 6 | capsule | Generic drugs (ANDA) | December 24, 2025 |
| Novadoz Pharmaceuticals LLC | 6 | tablet, chewable | Generic drugs (ANDA) | February 2, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 105 | 71.4% |
| Tablet, chewable | 42 | 28.6% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 134 | 91.2% |
| New drug applications (NDA) | 13 | 8.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Central Nervous System Stimulant | 147 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.